A Prospective, Comparative, Randomized, Multi-Center, Double-Blinded, Placebo-Controlled, Phase 2a Study of the Safety and Efficacy of CMX-2043 for Periprocedural Injury Protection in Subjects Undergoing Coronary Angiography at Risk of Radio-contrast Induced Nephropathy (CARIN)
Phase of Trial: Phase II
Latest Information Update: 03 May 2016
Price : $35 *
At a glance
- Drugs CMX 2043 (Primary)
- Indications Acute kidney injury; Heart disorders
- Focus Therapeutic Use
- Acronyms CARIN
- Sponsors Ischemix
- 03 May 2016 Primary endpoint, (Prevention of acute kidney injury (AKI) ) has not been met, according to an Ischemix media release.
- 03 May 2016 According to an Ischemix media release, company is reviewing post hoc analyses of certain patient subgroups for evidence of potential benefit of the drug.
- 22 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.